drugset
drugset / Trial / NCT04440007

Study of the Efficacy and Safety of STI-5656 (Abivertinib Maleate) in Subjects Hospitalized With COVID-19

NCT04440007 ↗

Phase 2 Completed 96 enrolled Sorrento Therapeutics, Inc.
RandomizedParallel-groupOpen-labelTreatment

Summary

Study to assess the safety and efficacy of STI-5656 (Abivertinib Maleate) plus SOC versus SOC in subjects hospitalized with COVID-19

Timeline

Start
2020-10-09
Primary completion
2021-07-01
Completion
2021-08-23

Drugs

EvaluationDrugModalityDoseRoute
Subject Abivertinib Small molecule 200 mg Oral

Indications

COVID-19